Team Lead, Cognitive Task Force
Place of work / study:
Syneos Health & University of Westminster
Area of research:
Cognition in AD / Clinical Trials
How is your work funded:
Self funded & Industry
Tell us a little about yourself:
I am currently working with PI’s and investigators on the phase III study of Elenbecestat, Eisai’s (and the fields only remaining) BACEi. Myself and my team look to interact with PIs on how to best find the right subjects for the trial and address high screen failures at sites as early as possible. Concurrently to this I am also undertaking a PhD in cognition in early AD at the University of Westminster, where I am currently looking at the role cognitive reserve and commonly used measures have on predicating amyloid positivity, as well as other biomarkers.
Tell us a fun fact about yourself:
I used to DJ at university
Why did you choose to work in dementia?
When I started working in industry I gravitated towards AD and dementia in particular due to the big unmet need for patients. Having seen first hand the effects of dementia on my Nan it particularly hit home and led me to where I am today.